Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q4 FY2023 Earnings Presentation
18 slides from Alkem Laboratories's earnings presentation, May 19, 2023
Slide 1: Cover letter to stock exchanges
ALKEM LABORATORIES LTD. <8> ALKEM Regd, OffJce: AL.KEM HOUSE, Sl:lflapali Bapal Marg, Lower Parsi (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91 -22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 19th May, 2023 The Corp
Slide 2: Alkem reports Q4FY23 and FY23 results
~ ALKEM LABORATORIES LTD. Regd. Office: ALKEM HOUSE, Senapati Bapat Marg, Lower Pare! (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 ALKEM • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Press Release Alkem reports Q4
Slide 3: Operational Highlights: Domestic Business
~ ALKEM LABORATORIES LTD. Regd. Office: ALKEM HOUSE, Senapati Bapat Marg, Lower Pare! (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 ALKEM • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Operational Highlights Domesti
Slide 4: International Business
~ ALKEM LABORATORIES LTD. Regd. Office: ALKEM HOUSE, Senapati Bapat Marg, Lower Pare! (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 ALKEM • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 International Business In Q4FY
Slide 5: Q4FY23 and FY23 Conference Call
~ ALKEM LABORATORIES LTD. Regd. Office: ALKEM HOUSE, Senapati Bapat Marg, Lower Pare! (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 ALKEM • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Q4FY23 and FY23 Conference Cal
Slide 6: Investor Presentation Q4FY23
Investor Presentation Q4FY23 May 19, 2023
Slide 7: Safe Harbor Statement
Safe Harbor Statement <a> ALKEM This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assump
Slide 8: Key Highlights of FY23
Key Highlights of FY23 <a> ALKEM • Revenue from Operation grew by 9.1% during FY23, with EBITDA margin of 13.9% and Net Profit margin of 8.5% • India Business: As per IQVIA, Company’s sales in FY23 registered growth of 12.8% compared to IPM growth of 7.9% • Outperformed IPM growth by 498 basis point
Slide 9: Key Financial Highlights – Q4FY23 (Consolidated)
Key Financial Highlights – Q4FY23 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 20,113 17,187 29,026 24,839 Q4FY22 Q4FY23 International sales 8,570 7,411 Q4FY22 Q4FY23 Q4FY22 Q4FY23
Slide 10: Key Financial Highlights – Q4FY23 (Consolidated)
Key Financial Highlights – Q4FY23 (Consolidated) <a> ALKEM All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 16,471 3,372 3,533 14,525 58.5% 56.7% 13.6% 12.2% Q4FY22 Q4FY23 Q4FY22 Q4FY23 PBT (after exceptional item) PAT (after Minority Interest) Q4FY23 was impacted by except
Slide 11: Key Financial Highlights – FY23 (Consolidated)
Key Financial Highlights – FY23 (Consolidated) <a> ALKEM All figures in ₹ mn Particulars (₹ mn) FY23 FY22 YoY growth Revenue from Operations 115,993 106,342 9.1% Gross Profit 66,924 64,539 3.7% Gross Profit margin 57.7% 60.7% EBITDA 16,095 20,529 -21.6% EBITDA margin 13.9% 19.3% PBT before exception
Slide 12: India Business
India Business India Business: Q4FY23 Sales of ₹ 20,113 million (17.0% YoY growth) • India sales contributed 70.1% to total sales in Q4FY23 • As per IQVIA, In Q4FY23, the Company’s secondary sales grew by 22.5% significantly outperforming IPM growth of 14.9% YoY. • Exceptional performance across all
Slide 13: Secondary Sales Performance
Secondary Sales Performance <a> ALKEM Exemplary Performance in Almost Every Therapy in FY23 Market rank 1 3 3 2 Acute Therapies Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients 17.5% 18.4% 12.3% 12.4% 8.6% 6.2% 2.5% 3.5% - Alkem sales growth YoY1,2 - Indian pharma in
Slide 14: US Business
US Business <a> ALKEM US Business: Q4FY23 Sales of ₹ 5,916 million (9.2% YoY growth) • US sales contributed 20.6% to total sales in Q4FY23 • During the quarter, the US business registered growth in ₹ terms mainly on account of currency depreciation. • In Q4FY23, the Company filed 4 ANDAs with the US
Slide 15: US Business: Update on US FDA inspections
US Business <a> ALKEM Update on US FDA inspections Facility Capability Last inspection Status post last inspection Ankleshwar (India) API April 2023 Successfully closed inspection without any observations. St. Louis (US) Formulations November 2022 Inspection is closed. EIR# received in December 2022
Slide 16: Other International Business
Other International Business Other International Business: Q4FY23 Sales of ₹ 2,654 million (33.3% YoY growth) • Other International Market sales contributed 9.3 % to total sales in Q4FY23 • The Company has presence in Latin America, Australia, Europe, South East Asia, Africa and CIS. • All our major
Slide 17: Latest Shareholding Pattern
Latest Shareholding Pattern <a> ALKEM Shareholding pattern as on March 31, 2023 Non-Institution, 21.70% Promoter & Promoter Group, 57.16% Institution, 21.14% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public,
Slide 18: Thank You
<a> ALKEM Thank You For further information or queries, please contact Amit Kumar Khandelia AVP Finance Tel: +91 22 3982 9999 E-mail: amit.khandelia@alkem.com